Implantable Cardioverter Defibrillator Therapy in Patients with Cardiac Sarcoidosis

被引:111
|
作者
Schuller, Joseph L.
Zipse, Matthew
Crawford, Thomas
Bogun, Frank
Beshai, John
Patel, Amit R.
Sweiss, Nadera J.
Nguyen, Duy T.
Aleong, Ryan G.
Varosy, Paul D.
Weinberger, Howard D.
Sauer, William H.
机构
[1] Univ Colorado, Sect Cardiac Electrophysiol, Denver, CO 80202 USA
[2] Univ Michigan, Sect Cardiac Electrophysiol, Ann Arbor, MI 48109 USA
[3] Univ Chicago, Sect Cardiac Electrophysiol, Chicago, IL 60637 USA
关键词
cardiac sarcoid; cardiomyopathy; heart failure; implantable cardioverter defibrillator; ventricular tachycardia; PREVENTION; HEART;
D O I
10.1111/j.1540-8167.2012.02350.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ICD Shocks in Cardiac Sarcoidosis. Background: An implantable cardioverter defibrillator (ICD) is indicated for some patients with cardiac sarcoidosis (CS) for prevention of sudden death. However, there are little data regarding the event rates of ICD therapies in these patients. We sought to identify the incidence and characteristics of ICD therapies in this patient population. Methods: We performed a cohort study of patients with ICDs at 3 institutions. Cases were those patients with CS and an ICD implanted for primary or secondary prevention of sudden death. Additionally, we included a comparison with historical controls of ICD therapy rates reported in clinical trials evaluating the ICD for primary and secondary prevention of sudden death. Results: Of the 112 CS subjects identified, 36 (32.1%) received appropriate therapies for ventricular tachyarrhythmias (VT) over a mean follow-up period of 29.2 months. VT storm (>3 episodes in 24 hours) occurred in 16 (14.2%) CS subjects. Inappropriate therapies occurred in 13 CS subjects (11.6%). Covariates associated with appropriate ICD therapies included left ventricular ejection fraction (LVEF) <55% (OR 6.52 [95% CI 2.4317.5]), right ventricular dysfunction (OR 6.73 [95% CI 2.6916.8]), and symptomatic heart failure (OR 4.33 [95% CI 1.8610.1]). Conclusions: In our cohort of patients with CS and ICDs, almost one-third receive appropriate therapies. This may be due to a myocardial inflammatory process leading to increased triggered activity and subsequent scarring leading to reentrant tachyarrhythmias. Adjusted predictors of ICD therapies in this population include left or right ventricular dysfunction. (J Cardiovasc Electrophysiol, Vol. 23, pp. 925-929, September 2012)
引用
收藏
页码:925 / 929
页数:5
相关论文
共 50 条
  • [21] Pacemaker, cardiac resynchonisation, implantable cardioverter/defibrillator, event monitoring
    Klein, N.
    Klein, M.
    Pfeiffer, D.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (49) : 2526 - 2529
  • [22] Prevention of sudden cardiac death by the implantable cardioverter-defibrillator
    Hindricks, Gerhard
    Lenarczyk, Radoslaw
    Kalarus, Zbigniew
    Doering, Michael
    Shamloo, Alireza Sepehri
    Dagres, Nikolaos
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2018, 128 (12): : 764 - 770
  • [23] Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator
    Daubert, J. Claude
    Leclercq, Christophe
    Mabo, Philippe
    EUROPACE, 2009, 11 : 87 - 92
  • [24] Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis
    Lin, Grace
    Dispenzieri, Angela
    Kyle, Robert
    Grogan, Martha
    Brady, Peter A.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2013, 24 (07) : 793 - 798
  • [25] Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome
    Gierula, John
    Paton, Maria F.
    Witte, Klaus K.
    FUTURE CARDIOLOGY, 2021, 17 (04) : 609 - 618
  • [26] Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management
    Chia, Pow-Li
    Foo, David
    SINGAPORE MEDICAL JOURNAL, 2016, 57 (07) : 354 - 359
  • [27] Experience with implantable cardioverter defibrillator therapy in elderly patients
    Geelen, P
    Lorga, A
    Primo, J
    Wellens, F
    Brugada, P
    EUROPEAN HEART JOURNAL, 1997, 18 (08) : 1339 - 1342
  • [28] Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator
    Klein, Helmut U.
    Goldenberg, Ilan
    Moss, Arthur J.
    EUROPEAN HEART JOURNAL, 2013, 34 (29) : 2230 - 2242
  • [29] The dilemma of implantable cardioverter-defibrillator therapy in the geriatric population
    Revenco, Diana
    Morgan, James P.
    Tsao, Lana
    JOURNAL OF GERIATRIC CARDIOLOGY, 2011, 8 (03) : 195 - 200
  • [30] Efficacy of Additional Amiodarone Therapy in Patients with an Implantable Cardioverter-Defibrillator
    Matsumoto, Naomichi
    Kumagai, Koichiro
    Ogawa, Masahiro
    Matsuo, Kunihiro
    Yasuda, Tomoo
    Takashima, Hideo
    Mitsutake, Chiharu
    Muraoka, Soichi
    Matsunaga, Akira
    Miura, Shin-ichiro
    Saku, Keijiro
    JOURNAL OF ARRHYTHMIA, 2010, 26 (02) : 103 - 110